FederalDue Nov 4, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The BMFRP Idea Development Award (IDA) is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP’s vision of understanding and curing BMF diseases.
Distinctive Features:
This funding opportunity is open to Established Investigators (EIs) and Early-Career Investigators (ECIs). Reviewers will assess Principal Investigators (PIs) using distinct review criteria based on their eligibility as an EI or ECI.
Preliminary data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.
Amount not specifiedOfficial notice ↗ FederalDue Nov 4, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Reconstructive Transplant Research Program (RTRP) Concept Award supports the exploration of highly innovative new concepts or untested theories that address an important problem relevant to reconstructive transplantation. The Concept Award does not support clinical trials.
Distinctive Features:
· Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative.
· Relevance: Projects should address at least one of the FY26 RTRP Focus Areas.
· Preliminary Data: Presentation of preliminary data is not allowed; however, applications should demonstrate the ability to achieve interpretable results. A rationale for the proposed work must be provided.
· Early-Career Investigators: Early-career investigators are encouraged to apply. Investigators at or above the level of postdoctoral fellow are eligible to apply.
Amount not specifiedOfficial notice ↗ FederalDue Nov 5, 2026
Centers for Disease Control and Prevention - ERA
The NOFO supports CDC"s efforts to protect U.S. residents traveling internationally. The goal is to help U.S. travelers with pre-travel preparation, access to timely health information while traveling, and timely research on health conditions.The project will:Improve access to high quality travel preparation information for both healthcare providers and travelers.Collect health information before, during, and after travel through innovative electronic medical record (EMR), web, and mobile phone applications.Build on this platform to conduct timely research on emerging health threats.This NOFO will also increase the awareness of travel medicine among primary care providers and provide them with appropriate tools in advising international travelers with up-to-date recommendations.
$750,000 – $1,000,000Official notice ↗ FederalDue Nov 6, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Investigator-Initiated Research Award (IIRA) supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research. Research must address at least one of the four FY26 PRP Focus Areas.
Distinctive Features:
· Partnering Principal Investigator (PI) Option: Allows for more than one PI. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as Partnering PI(s), with a maximum of two Partnering PIs.
· Preliminary data are required.
· Clinical trials are allowed.
Amount not specifiedOfficial notice ↗ FederalDue Nov 6, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Parkinson’s Research Program (PRP) Early Investigator Research Award (EIRA) supports Parkinson’s disease (PD) research for investigators in the early stages of their careers. The FY26 EIRA offers two funding levels, which align to the research career stage of the Principal Investigator (PI). Funding Level 1 (for fellows) requires the investigator to receive guidance from a designated Mentor, whereas Funding Level 2 (for early-career independent investigators) does not. Proposed research must address at least one of the four FY26 PRP Focus Areas.
Distinctive Features:
· The Early Investigator is considered the PI of the application and must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of PD research; however, the PI is not required to have previous PD research experience.
· Funding Level 1: Applications must include at least one Mentor appropriate to the proposed research project who has experience in PD research and mentoring, as demonstrated by a record of active funding, recent publications, and successful mentorship. The selected Mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a PD researcher. Preliminary data are encouraged but not required.
· Funding Level 2: Mentor not required. Preliminary data are required.
· Clinical trials are not allowed.
Amount not specifiedOfficial notice ↗ FederalDue Nov 6, 2026
National Institutes of Health
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. This NOFO requests limited competition applications for a 3-year extension of the COPE-AKI clinical trial consortium, which includes three clinical centers (CCs) and one scientific and data research center (SDRC), to fully meet the enrollment targets, complete participant follow-up, and provide resources for data analysis and dissemination of study findings. There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
Amount not specifiedOfficial notice ↗ FederalDue Nov 6, 2026
Dept of the Army -- Materiel Command
Department of Army:
The Department of War (DoW) announces the Fiscal Year 2027 Defense University Research Instrumentation Program (DURIP). DURIP is designed to improve the capabilities of accredited United States (U.S.) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding.
$50,000 – $3,000,000Official notice ↗ FederalDue Nov 6, 2026
Office of Naval Research
In accordance with EO 14332, Improving Oversight of Federal Grantmaking, dated 7 August 2025, and EO 14303, Restoring Gold Standard Science, dated 23 May 2025, this Announcement seeks
proposals from universities to purchase equipment and instrumentation in support of research in areas of interest to the DoW, reflecting the basic research priorities for the Department of War and advancing the administration and agency priorities (c.f., OMB memo M-25-34 “Fiscal Year 2027 Administration Research and Development Budget Priorities and Cross-Cutting Actions”).
DoW interests include the areas of research supported by the Army Research Office (ARO), the Office of Naval Research (ONR), and the Air Force Office of Scientific Research (AFOSR).
A central purpose of the DURIP is to provide equipment and instrumentation to enhance research related education in areas of interest and priority to the DoW. Therefore, your proposal must address the impact of the equipment or instrumentation on your institution’s ability to educate students through research in disciplines important to DoW missions.
$50,000 – $3,000,000Official notice ↗ FederalDue Nov 6, 2026
Air Force Office of Scientific Research
The Department of Defense (DoD) announces the Fiscal Year 2027 Defense University Research Instrumentation Program (DURIP). DURIP is designed to improve the capabilities of accredited United States (U.S.) institutions of higher education to conduct research and to educate scientists and engineers in areas important to national defense, by providing funds for the acquisition of research equipment or instrumentation. For-profit organizations are not eligible for DURIP funding.
$50,000 – $7,000,000Official notice ↗ FederalDue Nov 9, 2026
Bureau of International Narcotics-Law Enforcement
The Bureau of International Narcotics and Law Enforcement Affairs (INL) of the U.S. Department of State announce an open competition for organizations to submit applications to carry out a project to develop a software-based weighted, random case-allocation system to prevent selective prosecution of transnational organized crime and money laundering cases. Political interference in the prosecution service remains a barrier to fighting transnational organized crime and achieving other U.S. objectives in Serbia. As requested by the High Prosecutorial Council, the body responsible for oversight of the prosecution service, this grant will reduce political manipulation of prosecutions and improve outcomes in extradition cases and cases involving high-level corruption and transnational criminal organization (TCO) leaders whose activities harm U.S. national security interests through random allocation of cases
$750,000 – $1,100,000Official notice ↗ FederalDue Nov 9, 2026
National Institutes of Health
Applications for a 3-year extension/renewal of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) clinical trial consortium are requested to fully meet the enrollment targets, complete participant follow-up, and finalize data analysis and dissemination of study findings. This Notice of Funding Opportunity (NOFO) invites a Single Source application for the eligible organization, the Scientific and Data Research Center (SDRC) already involved in the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.There is currently no standard of care for patients after hospitalization with acute kidney injury (AKI). Successful completion of the COPE-AKI study will provide key insights that are expected to directly inform improved clinical management strategies and the development of standard of care for Stage 2 and 3 AKI survivors.
Amount not specifiedOfficial notice ↗ FederalDue Nov 10, 2026
National Institutes of Health
The purpose of this notice of funding opportunity (NOFO) is to solicit applications for an Infectious Diseases Clinical Trials Network (IDCTN). The IDCTN, comprised of the Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC), supports the evaluation of interventions for emerging and chronic infections. The CTEUs design and implement clinical trials and studies, while the NCC provides the administrative and operational framework for a collaborative, integrated network and engages with experts in the field to solicit and generate clinical trial concepts. The NCC and CTEUs will collaboratively create opportunities to advance investigators early in their careers and those new to the field.
Amount not specifiedOfficial notice ↗ FederalDue Nov 10, 2026
National Institutes of Health
The purpose of this notice of funding opportunity (NOFO) is to support a Clinical Research Network (CRN) on Antimicrobial Resistance (AMR). The program aims to design, implement, and manage clinical research that addresses pivotal clinical questions related to AMR through a coordinated and integrated CRN. The CRN will comprise four centers: the Scientific Leadership Center (SLC), the Clinical Operations Center (COC), the Laboratory Center (LC), and the Statistics and Data Coordination Center (SDCC).
Amount not specifiedOfficial notice ↗ FederalDue Nov 10, 2026
National Institutes of Health
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies offering new capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens for basic, clinical, or epidemiological cancer research. The NOFO solicits R61 applications for early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. Technologies proposed for development may have potential for widespread applicability but must be focused for this program on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
FederalDue Nov 10, 2026
National Institutes of Health
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites grant applications proposing exploratory research projects focused on further development and technical validation of emerging technologies offering novel capabilities for the molecular or cellular characterization of cancer or for improved handling and quality control of biospecimens used for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous technical validation to encourage adoption by the research community. Well-suited applications must propose the development of technologies that offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer-relevant use cases. Projects proposing to apply or use existing technologies for hypothesis-driven research where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.
FederalDue Nov 10, 2026
National Institutes of Health
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of spinal cord injury (SCI).
Distinctive Features: This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the Initiating PI will submit a pre-application, but all PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners (e.g., SCI Lived-Experience Consultants, representatives of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA) supports translational research that will accelerate the movement of promising ideas in spinal cord injury (SCI) research into clinical applications.
Distinctive Features:
• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
• Applications to this funding opportunity must name at least one SCI community partner (e.g., SCI Lived-Experience Consultant, representative of community-based organizations) who will provide advice and consultation throughout the planning and implementation of the research project.
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) supports high-impact, new, or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation. Primary objectives of this mechanism include:
• Accelerating the translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.
• Identifying the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care partners and policymakers.
Distinctive Features:
• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
• Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners who will provide advice and consultation throughout the planning and implementation of the research project.
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details.
· Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication.
· Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health.
https://cdmrp.health.mil/pubs/press/2026/vrppreann
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Translational Research Award (TRA) supports translational research that transforms a promising discovery into new drugs, devices or clinical practice guidelines that are ready for definitive testing in clinical trials during or by the end of the period of performance. The TRA may be used to support preclinical studies, clinical research or a pilot clinical trial, but not a full-scale clinical trial. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· If developing new drugs or device(s), the research team must include expertise in the regulatory approval process.
· The TRA includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI.
· Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, Personnel and Post-Award Transition Plan.
· Programmatic review criteria include adherence to the intent of the TRA, contribution to the VRP portfolio, relative impact and relevance to military health.
· The VRP may share FY26 TRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration.
https://cdmrp.health.mil/pubs/press/2026/vrppreann
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Investigator-Initiated Research Award (IIRA) supports studies that have the potential to make an important contribution to spinal cord injury (SCI) research, patient care and/or quality of life. May focus on any phase of research from basic through translational science, though studies that focus solely on identifying intervention targets are discouraged.
Distinctive Features:
• This funding opportunity contains an Early-Career Partnership Option, which allows for two Principal Investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. If recommended for funding, each PI will be named on a separate award to the recipient organization(s). Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Amount not specifiedOfficial notice ↗ FederalDue Nov 12, 2026
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Investigator-Initiated Research Award (IIRA) supports basic through early translational research that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction related to military exposure. The IIRA may be used to support preclinical studies and/or clinical research. Research must align with at least one of the FY26 VRP Focus Areas. The IIRA cannot be used to support clinical trials.
Distinctive Features:
· The IIRA offers two Funding Levels to support research at different stages and the exploration/development of ideas of different maturity levels.
· Funding Level 2 includes a Partnering Principal Investigator (PI) Option (PPIO) for two PIs, an Initiating PI and a Partnering PI.
· Scored peer review criteria include Research Idea/Rationale, Research Strategy and Feasibility, Impact, and Personnel.
· Programmatic review criteria include adherence to the intent of the IIRA, contribution to the VRP portfolio, relative impact, and relevance to military health.
· The VRP may share FY26 IIRA applications and reviews with the National Eye Institute (NEI) for independent funding consideration.
https://cdmrp.health.mil/pubs/press/2026/vrppreann
Amount not specifiedOfficial notice ↗ FederalDue Nov 13, 2026
Institute of Museum and Library Services
The Native American/Native Hawaiian Museum Services program (NANH) supports Native American Tribes, Alaska Native Villages, and organizations that primarily serve and represent Native Hawaiians in sustaining heritage, culture, and knowledge. The program supports projects such as educational services and programs, workforce professional development, organizational capacity building, community engagement, and collections stewardship.
$5,000 – $250,000Official notice ↗